Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver cancer
Pharma
BMS follows Roche, AstraZeneca into first-line liver cancer
With the nod, BMS' Opdivo and Yervoy will go toe-to-toe with Roche's Tecentriq-Avastin and AstraZeneca's Imfinzi-Imjudo in first-line liver cancer.
Angus Liu
Apr 11, 2025 1:53pm
FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
Mar 21, 2025 3:25pm
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
Sep 14, 2024 10:30am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
ASCO: Bristol calls Roche and AZ's bets in 1L liver cancer
Jun 4, 2024 8:00am
